appliedclinicaltrialsonline1h
ASTRO Trial Shows SC Tremfya Provides Significant Clinical Benefits in Moderately to Severely Active Ulcerative Colitis
Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...
Microbiotica unveils data on the mechanism of action of MB310, a clinical-stage drug candidate in development for the treatment of ulcerative colitis
MB310 has been developed as an oral capsule, dosed once daily, containing a defined consortium of eight live gut commensal bacterial strains. It is designed to deliver long-term remission to UC ...
Can AI Unlock New Treatment Possibilities For Inflammatory Bowel Disease? How Johnson & Johnson Is Leading The Way
Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...
Devonian Announces the Filing of a New Patent Application Relating to the Use of Thykamine™ as an Antifibrotic Agent
Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on ...
Business Wire7d
Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine™ for Treating Metabolic Dysfunction-Associated Steatohepati…
Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on ...